Skip to main content

Zolpidem pharmacotherapy combined with alpha-blocker therapy for nocturia unresponsive to alpha-blocker monotherapy in men with lower urinary tract symptoms: a preliminary study



The aim of the present study was to determine whether administration of zolpidem, a nonbenzodiazepine sedative-hypnotic agent, at night would improve the frequency of nocturia unresponsive to alpha-blocker monotherapy in men with lower urinary tract symptoms (LUTS).

Materials and methods

The study inclusion criteria were: age ≥50 years, nocturia twice or more per night (International Prostate Symptom Score [IPSS] question 7) after taking alpha-blockers for more than eight weeks, and incomplete frequency-flow chart (FVC). A total of 18 patients met the criteria and constituted the study cohort. Three patients were given 0.2 mg tamsulosin once daily and others were given 4 mg terazosin once daily. All patients were additionally administered 10 mg zolpidem once at night for the eight weeks.


There were no serious side-effects in any patient. Nocturia decreased from a baseline median (25–75th percentiles) of 3 (3–5) to 3 (3–4.5) episodes after taking alpha-blockers (p = 0.129) and to 2 (1–3) episodes after taking zolpidem and alpha-blockers (p = 0.001) on the IPSS. After treatment, the scores of uroflowmetry values did not significantly changed. However, at eight weeks, voiding symptoms (p = 0.041) and total IPSS scores (p = 0.028) significantly decreased compared with those at baseline. Median (25–75th percentiles) quality-of-life (QoL) index changed from 5 (4–5) at baseline to 3 (3–3) after eight weeks of treatment (p = 0.005).


Our results indicate that zolpidem resulted in a subjective reduction in nocturia episodes when given to some men with LUTS.

This is a preview of subscription content, access via your institution.

Fig. 1


  1. 1.

    van Kerrebroeck P, Abrams P, Chaikin D et al (2002) The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:179–183

    PubMed  Article  Google Scholar 

  2. 2.

    Asplund R, Aberg H (1992) Health of the elderly with regard to sleep and nocturnal micturition. Scand J Prim Health Care 10:98–104

    PubMed  Article  CAS  Google Scholar 

  3. 3.

    Yoshimura K, Ohara H, Ichioka K et al (2003) Nocturia and benign prostatic hyperplasia. Urology 61:786–790

    PubMed  Article  Google Scholar 

  4. 4.

    Homma Y, Yamaguchi T, Kondo Y et al (2002) Significance of nocturia in the International Prostate Symptom Score for benign prostatic hyperplasia. J Urol 167:172–176

    PubMed  Article  Google Scholar 

  5. 5.

    Bruskewitz RC, Larsen EH, Madsen PO et al (1986) 3-year followup of urinary symptoms after transurethral resection of the prostate. J Urol 136:613–615

    PubMed  CAS  Google Scholar 

  6. 6.

    Larsson G, Victor A (1988) Micturition patterns in a healthy female population, studied with a frequency/volume chart. Scand J Urol Nephrol Suppl 114:53–57

    PubMed  CAS  Google Scholar 

  7. 7.

    Abrams P, Klevmark B (1996) Frequency volume charts. An indispensable part of lower urinary tract assessment. Scand J Urol Nehrol Suppl 179:47–53

    CAS  Google Scholar 

  8. 8.

    Larsson G, Abrams P, Victor A (1998) The frequency/volume chart in detrusor instability. Neurourol Urodyn 1:533–543

    Google Scholar 

  9. 9.

    Robinson D, McClish DK, Wyman JF et al (1996) Comparison between urinary diaries completed with and without intensive patient instructions. Neurourol Urodyn 15:143–148

    PubMed  Article  CAS  Google Scholar 

  10. 10.

    Weiss JP, Blaivas JG, Stember DS et al (1998) Nocturia in adults: etiology and classification. Neurourol Urodyn 17:467–472

    PubMed  Article  CAS  Google Scholar 

  11. 11.

    Ku JH, Jeong IG, Lim DJ et al (2004) Voiding diary for the evaluation of urinary incontinence and lower urinary tract symptoms: prospective assessment of patient compliance and burden. Neurourol Urodyn 23:331–335

    PubMed  Article  Google Scholar 

  12. 12.

    Drake MJ, Mills IW, Noble JG (2004) Melatonin pharmacotherapy for nocturia in men with benign prostatic enlargement. J Urol 171:1199–1202

    PubMed  Article  CAS  Google Scholar 

  13. 13.

    Abrams P (1999) Bladder outlet obstruction index, bladder contractility index and bladder voiding efficiency: three simple indices to define bladder voiding function. BJU Int 84:14–15

    PubMed  Article  CAS  Google Scholar 

  14. 14.

    Hodgson LA (1991) Why do we need sleep? Relating theory to nursing practice. J Adv Nurs 16:1503–1510

    PubMed  Article  CAS  Google Scholar 

  15. 15.

    Nicolau MC, Akaarir M, Gamundi A et al (2000) Why we sleep: the evolutionary pathway to the mammalian sleep. Prog Neurobiol 62:379–406

    PubMed  Article  CAS  Google Scholar 

  16. 16.

    Sejnowski TJ, Destexhe A (2000) Why do we sleep? Brain Res 886:208–223

    PubMed  Article  CAS  Google Scholar 

  17. 17.

    Broman JE, Lundh LG, Hetta J (1996) Insufficient sleep in the general population. Neurophysiol Clin 20:30–39

    Article  Google Scholar 

  18. 18.

    Middelkoop HA, Smulde-van den Doel DA, Neven AK et al (1996) Subjective sleep characteristics of 1485 males and females aged 50–93: effects of sex and age, and factors related to self-evaluated quality of sleep. J Gerontol Biol Sci Med Sci 51:M108-M115

    CAS  Google Scholar 

  19. 19.

    Benca RM (2005) Diagnosis and treatment of chronic insomnia: a review. Psychiatr Serv 56:332–343

    PubMed  Article  Google Scholar 

  20. 20.

    Walsh JK, Erman M, Erwin CW et al (1998) Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia. Hum Psychopharmacol 13:191–198

    Article  CAS  Google Scholar 

  21. 21.

    Scharf MB, Roth T, Vogel GW et al (1994) A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 55:192–199

    PubMed  CAS  Google Scholar 

  22. 22.

    Walsh JK, Roth T, Randazzo A et al (2000) Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep 23:1087–1096

    PubMed  CAS  Google Scholar 

  23. 23.

    Perlis ML, McCall WV, Krystal AD et al (2004) Longterm, non-nightly administration of zolpidem in the treatment of patients with primary insomnia. Clin Psychiatry 65:1128–1137

    CAS  Google Scholar 

  24. 24.

    Kummer J, Guendel L, Linden J et al (1993) Long-term polysomnographic study of the efficacy and safety of zolpidem in elderly psychiatric in-patients with insomnia. J Int Med Res 21:171–184

    PubMed  CAS  Google Scholar 

  25. 25.

    Asnis GM, Chakraburtty A, DuBoff EA et al (1999) Zolpidem for persistent insomnia in SSRI-treated depressed patients. J Clin Psychiatry 60:668–676

    PubMed  CAS  Article  Google Scholar 

  26. 26.

    Schlich D, L’Heritier C, Coquelin JP et al (1991) Long-term treatment of insomnia with zolpidem: a multicentre general practitioner study of 107 patients. J Int Med Res 19:271–279

    PubMed  CAS  Google Scholar 

  27. 27.

    Matthiesen T, Rittig S, Norgaard JP et al (1996) Nocturnal polyuria and natriuresis in male patients with nocturia and lower urinary tract symptoms. J Urol 156:1292–1299

    PubMed  Article  CAS  Google Scholar 

  28. 28.

    Paick JS, Ku JH, Shin JW et al (2006) alpha-blocker monotherapy in the treatment of nocturia in men with lower urinary tract symptoms: a prospective study of response prediction. BJU Int 97:1017–1023

    PubMed  Article  CAS  Google Scholar 

  29. 29.

    Tanaka Y, Masumori N, Itoh N et al (2002) Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia. J Urol 167:2492–2495

    PubMed  Article  CAS  Google Scholar 

  30. 30.

    Okada H, Kamidono S, Yoshioka T et al (2000) A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients. BJU Int 85:676–681

    PubMed  Article  CAS  Google Scholar 

  31. 31.

    Lee E, Lee C (1997) Clinical comparison of selective and non-selective alpha 1Aadrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol 80:606–611

    PubMed  CAS  Google Scholar 

  32. 32.

    McConnell JD, Barry MJ, Bruskewitz RC et al (1994) Benign Prostatic Hyperplasia: diagnosis and treatment. Clinical practice guideline, no. 8. AHCPR publication no. 94–0582. Rockville, MD, Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services

  33. 33.

    Hansen BJ, Meyhoff HH, Nordling J et al (1996) Placebo effects in the pharmacological treatment of uncomplicated benign prostatic hyperplasia. Scand J Urol Nephrol 30:373–377

    PubMed  Article  Google Scholar 

  34. 34.

    Reynard JM, Cannon A, Yang Q et al (1998) A novel therapy for nocturnal polyuria: a double-blind randomized trial of frusemide against placebo. Br J Urol 81:215–218

    PubMed  CAS  Google Scholar 

  35. 35.

    Mattiasson A, Abrams P, Van Kerrebroeck P et al (2002) Efficacy of desmopressin in the treatment of nocturia: a double-blind placebocontrolled study in men. BJU Int 89:855–862

    PubMed  Article  CAS  Google Scholar 

  36. 36.

    Asplund R, Sundberg B, Bengtsson P (1999) Oral desmopressin for nocturnal polyuria in elderly subjects: a doubleblind, placebo-controlled randomized exploratory study. BJU Int 83:591–595

    PubMed  Article  CAS  Google Scholar 

Download references


This study was supported by the Korean Continence Society-Ferring grant, #KCSF 06-02.

Author information



Corresponding author

Correspondence to Ja Hyeon Ku.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Song, Y.S., Ku, J.H. Zolpidem pharmacotherapy combined with alpha-blocker therapy for nocturia unresponsive to alpha-blocker monotherapy in men with lower urinary tract symptoms: a preliminary study. Int Urol Nephrol 39, 1147–1152 (2007).

Download citation


  • Nocturia
  • Bladder
  • Urination disorders
  • IPSS
  • Zolpidem
  • Alpha-blocker